Breaking News Instant updates and real-time market news.

SYK

Stryker

$186.29

4.245 (2.33%)

16:08
04/23/19
04/23
16:08
04/23/19
16:08

Stryker reports Q1 adjusted EPS $1.88, consensus $1.84

Reports Q1 revenue $3.52B, consensus $3.52B.

  • 23

    Apr

  • 01

    May

  • 08

    May

  • 29

    May

SYK Stryker
$186.29

4.245 (2.33%)

03/15/19
BARD
03/15/19
NO CHANGE
BARD
Stryker, Wright Medical best positioned in medical robotics, says Baird
Following meetings at American Academy of Orthopaedic Surgeons this week, Baird analyst Jeff Johnson said that Stryker (SYK) remained the "clear robotics leader," and added that Smith & Nephew (SNN), Zimmer Biomet (ZBH), and to a lesser extent Johnson & Johnson (JNJ) were all "making progress." The analyst came away most positive on Stryker, due to momentum in multiple pipelines, and Wright Medical (WMGI), due to its core business strength and its intriguing pipeline. Johnson has an Outperform rating and $201 price target on Stryker, and Outperform rating and $36 price target on Wright Medical Group.
03/18/19
BTIG
03/18/19
NO CHANGE
Target $211
BTIG
Buy
Stryker price target raised to $211 from $191 at BTIG
BTIG analyst Ryan Zimmerman raised his price target on Stryker to $211 and kept his Buy rating after its presentation at the recent AAOS conference, saying he is "encouraged" by the company's core business area execution and believes that the adoption of its Mako surgery technology should "continue at a strong pace in FY19". In spite of the increasing competition, the analyst says the management expressed that it has "no plans to change the strategy even in the midst of increasing competition" but rather "noted a slight procedural volume uptick in joint reconstruction".
03/19/19
JPMS
03/19/19
NO CHANGE
Target $215
JPMS
Overweight
Stryker price target raised to $215 from $200 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Stryker to $215 from $200 and reiterates an Overweight rating on the shares. The analyst says that after a "bullish" management dinner, booth tour, and investor meeting, he's even more confident that Stryker can sustain its momentum for the balance of 2019 and a "healthy level" in 2020. The company exited 2018 in a position of strength following a year of peer-high organic growth and operating margin expansion despite meaningful acquisition dis-synergies, Marcus tells investors in a research note partially titled "There's Bullish, and Then There's Stryker's Messaging at AAOS."
04/01/19
WELS
04/01/19
NO CHANGE
Target $219
WELS
Outperform
Stryker price target raised to $219 from $214 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Stryker to $219 from $214 following his monthly MAKO Surgeon Tracker, that analyzes trends in surgeon training. The analyst notes that surgeon training for Stryker's MAKO Total Knee Application was up 1.2% in March month over month as compared to up 2.7% in February. There is typical quarter-to-quarter variation in surgeon training and Biegelsen expects normalized growth going forward versus the high-growth seen in the initial quarters post launch. The analyst continues to believe there is runway for growth as MAKO remains vastly underpenetrated both from a system placement and procedure volume standpoint, globally. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

OTLK

Outlook Therapeutics

$1.95

-0.05 (-2.50%)

08:05
08/20/19
08/20
08:05
08/20/19
08:05
Hot Stocks
Outlook Therapeutics completes patient enrollment for NORSE 1 Phase 3 trial »

Outlook Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 12

    Sep

BTAI

BioXcel Therapeutics

$8.73

-0.5 (-5.42%)

08:04
08/20/19
08/20
08:04
08/20/19
08:04
Hot Stocks
BioXcel Therapeutics awarded grant by U.S. DoD for BXCL501 development »

BioXcel Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SOLY

Soliton

$11.07

0.63 (6.03%)

08:03
08/20/19
08/20
08:03
08/20/19
08:03
Hot Stocks
Soliton announces results from preclinical studies of RAP treatment »

Soliton announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRSN

Mersana Therapeutics

$2.71

(0.00%)

08:03
08/20/19
08/20
08:03
08/20/19
08:03
Hot Stocks
Mersana Therapeutics intitiates expansion portion of Phase 1 study of XMT-1536 »

Mersana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIGR

Eiger BioPharmaceuticals

$10.43

0.16 (1.56%)

08:02
08/20/19
08/20
08:02
08/20/19
08:02
Hot Stocks
Eiger BioPharmaceuticals receives FDA BTD for for peginterferon lambda »

Eiger BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIQT

LiqTech

$6.44

-0.81 (-11.17%)

08:02
08/20/19
08/20
08:02
08/20/19
08:02
Hot Stocks
LiqTech announces SPA to acquire BS Plastic »

LiqTech International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 12

    Sep

CACI

CACI

$209.74

1.42 (0.68%)

08:01
08/20/19
08/20
08:01
08/20/19
08:01
Upgrade
CACI rating change  »

CACI upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VST

Vistra Energy

$23.68

-0.02 (-0.08%)

08:00
08/20/19
08/20
08:00
08/20/19
08:00
Hot Stocks
Vistra Energy to acquire Ambit Energy for $475M »

Vistra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

CNHI

CNH Industrial

$9.37

0.555 (6.30%)

08:00
08/20/19
08/20
08:00
08/20/19
08:00
Options
CNH Industrial call buyer realizes 150% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$143.66

-0.23 (-0.16%)

07:59
08/20/19
08/20
07:59
08/20/19
07:59
Recommendations
Salesforce analyst commentary  »

Salesforce sets up for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

07:57
08/20/19
08/20
07:57
08/20/19
07:57
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$61.34

0.14 (0.23%)

07:55
08/20/19
08/20
07:55
08/20/19
07:55
Downgrade
Vornado rating change  »

Vornado downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

07:55
08/20/19
08/20
07:55
08/20/19
07:55
General news
U.S. chain store sales fell 0.2% in the week ended August 17 »

U.S. chain store sales…

ANAB

AnaptysBio

07:53
08/20/19
08/20
07:53
08/20/19
07:53
Recommendations
AnaptysBio analyst commentary  »

Cantor says AnaptysBio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOVA

Sunnova Energy

$11.13

0.089 (0.81%)

07:53
08/20/19
08/20
07:53
08/20/19
07:53
Initiation
Sunnova Energy initiated  »

Credit Suisse bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$201.74

22.48 (12.54%)

07:50
08/20/19
08/20
07:50
08/20/19
07:50
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

IMMU

Immunomedics

$14.83

-0.11 (-0.74%)

07:49
08/20/19
08/20
07:49
08/20/19
07:49
Initiation
Immunomedics initiated  »

Cantor Fitzgerald starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

LVS

Las Vegas Sands

$54.67

2.28 (4.35%)

07:49
08/20/19
08/20
07:49
08/20/19
07:49
Downgrade
Las Vegas Sands rating change  »

Las Vegas Sands cut to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SILK

Silk Road Medical

$40.85

0.28 (0.69%)

07:44
08/20/19
08/20
07:44
08/20/19
07:44
Initiation
Silk Road Medical initiated  »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

IQ

iQIYI

$18.10

1.02 (5.97%)

07:42
08/20/19
08/20
07:42
08/20/19
07:42
Downgrade
iQIYI rating change  »

iQIYI downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

07:41
08/20/19
08/20
07:41
08/20/19
07:41
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNET

ChinaNet Online

$1.50

0.135 (9.89%)

07:41
08/20/19
08/20
07:41
08/20/19
07:41
Hot Stocks
ChinaNet CEO says will continue to integrate blockchain, AI tech into products »

CEO Handong Cheng,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$201.74

22.48 (12.54%)

07:37
08/20/19
08/20
07:37
08/20/19
07:37
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

VVUS

VIVUS

$3.46

-0.02 (-0.57%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Hot Stocks
VIVUS says study shows addition of Qsymia to LSG surgery improved weight loss »

VIVUS announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$125.55

0.73 (0.58%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Recommendations
Splunk analyst commentary at Wedbush »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 15

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.